An introduction to ICURe

by Don Spalinger

Don Spalinger, Director, ICURe Programme

Key FactsDon Spalinger

  • Open to universities through the UK
  • Gets researchers out of the lab and into the marketplace
  • Determine market validation for commercialisation of research results
  • Funding up to £35k for each team
  • Application Form to apply for the next cohort

Our award-winning ICURe innovation to commercialisation programme is a game-changer in helping university researchers get their ideas out of the laboratory and into the marketplace.

In collaborating with our funding partner, Innovate UK, we are provided university academics with a real opportunity to test, establish and grow the commercial potential of their research. ICURe offers exceptional training and team support, engagement with prospective customers, partners and competitors, and validation of commercial potential, over an intensive three month period. It is a highly effective avenue for universities to begin to demonstrate the IMPACT of their research quickly.

The programme has supported the launch of new spin-out companies which have found commercial traction and that serve a real need in society. However, ICURe is not just about start-up companies – all of the participating teams have come away with a clear understanding of what the marketplace needs and how their research can impact those needs.  Some teams find licensing their technology the appropriate commercialisation path.  Others find their ideas need more work, and they secure further research funding, frequently collaborative research funding from companies that they discovered during their ICURe journey. Originally ICURe was piloted by SETsquared Partnership universities, and much success was demonstrated. This success enabled us to widen our reach and welcome more teams from universities throughout the UK, fulfilling our objectives of enhancing the commercial knowledge and skills of academic researchers and filling the universities’ pipelines with new potential UK spin-outs, lucrative licensing arrangements, and new sources of collaborative research funding.